Trade Relmada Therapeutics, Inc. - RLMD CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Relmada Therapeutics Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 2.86 |
| Open* | 2.89 |
| 1-Year Change* | -44.21% |
| Day's Range* | 2.83 - 2.89 |
| 52 wk Range | 1.81-5.75 |
| Average Volume (10 days) | 114.66K |
| Average Volume (3 months) | 3.40M |
| Market Cap | 88.49M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 30.10M |
| Revenue | N/A |
| EPS | -3.71 |
| Dividend (Yield %) | N/A |
| Beta | 0.13 |
| Next Earnings Date | Mar 21, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 27, 2023 | 2.84 | 0.00 | 0.00% | 2.84 | 2.89 | 2.83 |
| Nov 24, 2023 | 2.86 | 0.05 | 1.78% | 2.81 | 2.91 | 2.81 |
| Nov 22, 2023 | 2.85 | -0.08 | -2.73% | 2.93 | 2.96 | 2.82 |
| Nov 21, 2023 | 2.93 | 0.05 | 1.74% | 2.88 | 2.98 | 2.72 |
| Nov 20, 2023 | 2.89 | 0.07 | 2.48% | 2.82 | 2.97 | 2.82 |
| Nov 17, 2023 | 2.78 | -0.09 | -3.14% | 2.87 | 2.93 | 2.78 |
| Nov 16, 2023 | 2.93 | -0.05 | -1.68% | 2.98 | 3.01 | 2.84 |
| Nov 15, 2023 | 2.99 | 0.06 | 2.05% | 2.93 | 3.14 | 2.90 |
| Nov 14, 2023 | 2.89 | 0.11 | 3.96% | 2.78 | 2.95 | 2.78 |
| Nov 13, 2023 | 2.80 | -0.05 | -1.75% | 2.85 | 2.87 | 2.68 |
| Nov 10, 2023 | 2.88 | -0.07 | -2.37% | 2.95 | 2.97 | 2.85 |
| Nov 9, 2023 | 2.95 | 0.03 | 1.03% | 2.92 | 3.06 | 2.89 |
| Nov 8, 2023 | 2.94 | 0.00 | 0.00% | 2.94 | 3.02 | 2.92 |
| Nov 7, 2023 | 3.02 | -0.21 | -6.50% | 3.23 | 3.23 | 2.97 |
| Nov 6, 2023 | 3.09 | 0.00 | 0.00% | 3.09 | 3.27 | 3.06 |
| Nov 3, 2023 | 3.14 | 0.07 | 2.28% | 3.07 | 3.27 | 3.03 |
| Nov 2, 2023 | 3.00 | 0.08 | 2.74% | 2.92 | 3.18 | 2.92 |
| Nov 1, 2023 | 2.97 | -0.06 | -1.98% | 3.03 | 3.03 | 2.86 |
| Oct 31, 2023 | 2.97 | 0.02 | 0.68% | 2.95 | 2.99 | 2.85 |
| Oct 30, 2023 | 2.97 | 0.00 | 0.00% | 2.97 | 3.01 | 2.92 |
Relmada Therapeutics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Thursday, March 21, 2024 | ||
| Time (UTC) 20:00 | Country US
| Event Q4 2023 Relmada Therapeutics Inc Earnings Release Q4 2023 Relmada Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2019 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 161.249 | 125.703 | 60.8387 | 16.5024 | 8.27161 |
| Selling/General/Admin. Expenses, Total | 47.9261 | 35.0819 | 24.8659 | 5.70317 | 4.758 |
| Research & Development | 113.323 | 90.6216 | 35.9727 | 7.02475 | 3.51361 |
| Unusual Expense (Income) | 3.77447 | 0 | |||
| Operating Income | -161.249 | -125.703 | -60.8387 | -16.5024 | -8.27161 |
| Interest Income (Expense), Net Non-Operating | -2.14635 | -0.04832 | 1.38228 | -0.81567 | 0.07506 |
| Gain (Loss) on Sale of Assets | |||||
| Other, Net | 6.35161 | 0 | 0 | ||
| Net Income Before Taxes | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Net Income After Taxes | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Net Income Before Extra. Items | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Net Income | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Income Available to Common Excl. Extra. Items | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Income Available to Common Incl. Extra. Items | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Diluted Net Income | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Diluted Weighted Average Shares | 29.6287 | 17.5527 | 15.5942 | 6.31177 | 10.5779 |
| Diluted EPS Excluding Extraordinary Items | -5.3004 | -7.16423 | -3.81272 | -2.74377 | -0.77488 |
| Diluted Normalized EPS | -5.3004 | -7.16423 | -3.81272 | -2.14577 | -0.77488 |
| Total Extraordinary Items | |||||
| Dividends per Share - Common Stock Primary Issue | 0 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 26.0267 | 28.1536 | 38.7024 | 38.7372 | 45.5121 |
| Selling/General/Admin. Expenses, Total | 12.2865 | 12.2926 | 11.8341 | 8.20805 | 14.5994 |
| Research & Development | 13.7402 | 15.861 | 26.8684 | 30.5291 | 30.9127 |
| Operating Income | -26.0267 | -28.1536 | -38.7024 | -38.7372 | -45.5121 |
| Interest Income (Expense), Net Non-Operating | 0.72377 | 1.83203 | 0.75806 | -0.68155 | -0.7745 |
| Net Income Before Taxes | -25.3029 | -26.3216 | -37.9444 | -39.4187 | -39.935 |
| Net Income After Taxes | -25.3029 | -26.3216 | -37.9444 | -39.4187 | -39.935 |
| Net Income Before Extra. Items | -25.3029 | -26.3216 | -37.9444 | -39.4187 | -39.935 |
| Net Income | -25.3029 | -26.3216 | -37.9444 | -39.4187 | -39.935 |
| Income Available to Common Excl. Extra. Items | -25.3029 | -26.3216 | -37.9444 | -39.4187 | -39.935 |
| Income Available to Common Incl. Extra. Items | -25.3029 | -26.3216 | -37.9444 | -39.4187 | -39.935 |
| Diluted Net Income | -25.3029 | -26.3216 | -37.9444 | -39.4187 | -39.935 |
| Diluted Weighted Average Shares | 30.0992 | 30.0992 | 30.1041 | 30.0637 | 29.9359 |
| Diluted EPS Excluding Extraordinary Items | -0.84065 | -0.87449 | -1.26044 | -1.31117 | -1.33402 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.84065 | -0.87449 | -1.26044 | -1.31117 | -1.33402 |
| Other, Net | 0 | 0 | 0 | 6.35161 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2019 | |
|---|---|---|---|---|---|
| Total Current Assets | 152.87 | 223.298 | 118.074 | 9.98438 | 116.94 |
| Cash and Short Term Investments | 148.323 | 211.91 | 117.091 | 9.21655 | 116.443 |
| Cash & Equivalents | 5.39591 | 44.4434 | 2.4954 | 9.21655 | 36.2785 |
| Total Receivables, Net | 0.51243 | 0.08638 | 0.07946 | 0.24708 | 0.07309 |
| Prepaid Expenses | 4.03519 | 11.3015 | 0.90319 | 0.52075 | 0.42386 |
| Total Assets | 152.905 | 223.326 | 118.186 | 10.2197 | 117.136 |
| Property/Plant/Equipment, Total - Net | 0 | 0.00126 | 0.00721 | 0.005 | |
| Note Receivable - Long Term | 0 | 0.08638 | 0.20314 | 0.16583 | |
| Other Long Term Assets, Total | 0.03488 | 0.02829 | 0.025 | 0.025 | 0.025 |
| Total Current Liabilities | 12.4689 | 15.0609 | 12.6035 | 2.60642 | 1.45785 |
| Accounts Payable | 5.26194 | 11.1925 | 8.34648 | 0.92436 | 0.52266 |
| Accrued Expenses | 7.20694 | 3.86842 | 4.25698 | 1.31786 | 0.82494 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0.3642 | 0.11025 |
| Other Current Liabilities, Total | 0 | 0 | |||
| Total Liabilities | 12.4689 | 15.0609 | 12.6035 | 2.60642 | 1.45785 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | |||||
| Total Equity | 140.436 | 208.265 | 105.583 | 7.61332 | 115.678 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.0301 | 0.02774 | 0.01633 | 0.03898 | 0.01446 |
| Additional Paid-In Capital | 602.517 | 513.304 | 284.882 | 119.237 | 235.523 |
| Retained Earnings (Accumulated Deficit) | -462.111 | -305.067 | -179.315 | -111.662 | -119.859 |
| Total Liabilities & Shareholders’ Equity | 152.905 | 223.326 | 118.186 | 10.2197 | 117.136 |
| Total Common Shares Outstanding | 30.0992 | 27.7402 | 16.3329 | 9.74464 | 14.457 |
| Long Term Debt | 0 | 0 | |||
| Total Preferred Shares Outstanding | 0 | 0 | |||
| Short Term Investments | 142.927 | 167.466 | 114.596 | 80.1648 | |
| Property/Plant/Equipment, Total - Gross | 0.0167 | 0.0167 | 0.0167 | ||
| Accumulated Depreciation, Total | -0.0167 | -0.01544 | -0.0117 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 109.101 | 122.004 | 135.532 | 152.87 | 187.106 |
| Cash and Short Term Investments | 106.267 | 118.529 | 132.442 | 148.323 | 184.152 |
| Cash & Equivalents | 6.6986 | 14.4693 | 28.8944 | 5.39591 | 42.5244 |
| Short Term Investments | 99.5685 | 104.06 | 103.548 | 142.927 | 141.628 |
| Total Receivables, Net | 0 | 0 | 0 | 0.51243 | 0 |
| Prepaid Expenses | 2.83404 | 3.47454 | 3.08958 | 4.03519 | 2.95374 |
| Total Assets | 109.149 | 122.038 | 135.566 | 152.905 | 187.122 |
| Property/Plant/Equipment, Total - Net | |||||
| Property/Plant/Equipment, Total - Gross | |||||
| Accumulated Depreciation, Total | |||||
| Note Receivable - Long Term | |||||
| Other Long Term Assets, Total | 0.04772 | 0.03459 | 0.03488 | 0.03488 | 0.0161 |
| Total Current Liabilities | 8.42222 | 10.7025 | 10.0973 | 12.4689 | 20.7771 |
| Accounts Payable | 2.85675 | 4.85362 | 4.42197 | 5.26194 | 10.4258 |
| Accrued Expenses | 5.56547 | 5.84885 | 5.67529 | 7.20694 | 10.3513 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 8.42222 | 10.7025 | 10.0973 | 12.4689 | 20.7771 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 100.727 | 111.336 | 125.469 | 140.436 | 166.345 |
| Common Stock | 0.0301 | 0.0301 | 0.0301 | 0.0301 | 0.02864 |
| Additional Paid-In Capital | 636.434 | 625.041 | 613.872 | 602.517 | 590.483 |
| Retained Earnings (Accumulated Deficit) | -535.738 | -513.735 | -488.432 | -462.111 | -424.167 |
| Total Liabilities & Shareholders’ Equity | 109.149 | 122.038 | 135.566 | 152.905 | 187.122 |
| Total Common Shares Outstanding | 30.0992 | 30.0992 | 30.0992 | 30.0992 | 28.642 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets, Total |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2019 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Cash From Operating Activities | -103.802 | -91.8734 | -27.8088 | -10.4979 | -6.41378 |
| Cash From Operating Activities | 0 | 0.00126 | 0.00375 | 0.00487 | 0.0022 |
| Non-Cash Items | 42.6489 | 41.7419 | 20.7942 | 5.30986 | 2.367 |
| Cash Taxes Paid | 0 | 0 | 0 | ||
| Cash Interest Paid | 0 | 0.00242 | 0.00593 | 0.00461 | |
| Changes in Working Capital | 10.5933 | -7.86471 | 10.8496 | 1.50548 | -0.58643 |
| Cash From Investing Activities | 19.7336 | -54.118 | -34.4477 | 0 | -80.1648 |
| Capital Expenditures | 0 | 0 | |||
| Cash From Financing Activities | 45.0205 | 187.939 | 28.4733 | 17.4755 | 113.641 |
| Issuance (Retirement) of Debt, Net | 0 | -0.11025 | -0.28517 | -0.25396 | |
| Net Change in Cash | -39.0475 | 41.948 | -33.7831 | 6.97761 | 27.062 |
| Issuance (Retirement) of Stock, Net | 44.6468 | 187.939 | 28.5836 | 17.7606 | 113.895 |
| Other Investing Cash Flow Items, Total | 19.7336 | -54.118 | -34.4477 | -80.1648 | |
| Financing Cash Flow Items | 0.37363 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -26.3216 | -157.044 | -119.099 | -79.6807 | -39.7458 |
| Cash From Operating Activities | -16.5051 | -103.802 | -67.9187 | -41.0559 | -19.4297 |
| Cash From Operating Activities | 0 | 0 | 0 | 0 | 0 |
| Non-Cash Items | 10.7301 | 42.6489 | 37.0181 | 20.8142 | 13.709 |
| Cash Taxes Paid | 0 | 0 | |||
| Cash Interest Paid | 0 | 0 | |||
| Changes in Working Capital | -0.91358 | 10.5933 | 14.1626 | 17.8106 | 6.60705 |
| Cash From Investing Activities | 40.0036 | 19.7336 | 21.3891 | -10.1682 | -10.0277 |
| Other Investing Cash Flow Items, Total | 40.0036 | 19.7336 | 21.3891 | -10.1682 | -10.0277 |
| Cash From Financing Activities | 0 | 45.0205 | 44.6106 | 44.0415 | 29.9484 |
| Issuance (Retirement) of Stock, Net | 0 | 44.6468 | 44.6106 | 44.0415 | 29.9484 |
| Issuance (Retirement) of Debt, Net | |||||
| Net Change in Cash | 23.4985 | -39.0475 | -1.91907 | -7.18257 | 0.49094 |
| Financing Cash Flow Items | 0.37363 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Deep Track Capital LP | Hedge Fund | 9.4282 | 2837818 | 0 | 2023-06-30 | MED |
| RTW Investments L.P. | Investment Advisor/Hedge Fund | 7.0827 | 2131835 | 0 | 2023-06-30 | LOW |
| Kotler (Kevin) | Individual Investor | 6.3122 | 1899930 | 1899930 | 2022-12-12 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.3524 | 1310035 | -194944 | 2023-06-30 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 4.0579 | 1221399 | 0 | 2023-06-30 | MED |
| Parsons Capital Management, Inc. | Investment Advisor | 2.9014 | 873312 | 151146 | 2023-06-30 | |
| Palo Alto Investors LP | Hedge Fund | 2.4333 | 732400 | 190300 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.9646 | 591314 | -1103836 | 2023-06-30 | LOW |
| Citadel Advisors LLC | Hedge Fund | 1.9529 | 587794 | -82239 | 2023-06-30 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 1.8292 | 550586 | -211289 | 2023-06-30 | HIGH |
| Millennium Management LLC | Hedge Fund | 1.1428 | 343975 | 141647 | 2023-06-30 | HIGH |
| GSA Capital Partners LLP | Hedge Fund | 0.9021 | 271524 | 208926 | 2023-06-30 | HIGH |
| Mirae Asset Global Investments (USA) LLC | Investment Advisor | 0.8605 | 259009 | -79936 | 2023-09-30 | LOW |
| Horizons ETFs Management (Canada) Inc. | Investment Advisor/Hedge Fund | 0.8605 | 259009 | -71228 | 2023-09-30 | MED |
| BofA Global Research (US) | Research Firm | 0.7871 | 236901 | 199567 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7786 | 234362 | -267981 | 2023-06-30 | LOW |
| DWS Investments UK Limited | Investment Advisor | 0.747 | 224846 | -14106 | 2023-06-30 | LOW |
| RBF Capital, LLC | Hedge Fund | 0.6448 | 194074 | 194074 | 2023-06-30 | LOW |
| Kelly (Paul Edward) | Individual Investor | 0.6223 | 187295 | 0 | 2023-03-28 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 0.5397 | 162436 | -11415 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Relmada Therapeutics, Inc. Company profile
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of esmethadone (REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. REL-1017, is a NMDA receptor (NMDAR) channel blocker that targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. The Company's clinical program for REL-1017 evaluates its potential as a rapid-acting, oral, once-daily antidepressant treatment.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Relmada Therapeutics Inc revenues was not reported. Net loss increased from $59.5M to $125.8M. Higher net loss reflects Research and development - increase from $31.9M to $74.8M (expense), Stock-based Compensation in R&D increase from $4M to $15.8M (expense), Stock-based Compensation in SGA increase of 47% to $24.7M (expense).
Equity composition
.
| Industry: | Bio Therapeutic Drugs |
2222 Ponce De Leon Blvd. 3Rd Floor
CORAL GABLES
FLORIDA 33134
US
Income Statement
- Annual
- Quarterly
News
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023
XAU/USD Latest: Gold advances as weaker data weighs on US yields
Gold moves higher as softer economic data weighs on US yields and the dollar
13:43, 17 November 2023
Crude prices extend tumble as demand fears loom ahead of next OPEC+ meeting
Crude has extended its sell-off as demand risks loom ahead of OPEC+’s meeting on November 26. We look at the drivers of oil prices and the key technical levels of WTI Crude.
13:07, 17 November 2023
AUD/USD Retests Key Resistance Zone
The US dollar weakened notably following the latest CPI data, showing a larger-than-expected dip to 3.2% in October. This decline, the first in four months, sparked a surge in AUD/USD on Tuesday, pushing prices back into a crucial resistance zone established since August (see daily candle chart below).
10:24, 17 November 2023
Strategy Smarts Part 2: Trading Trend Days
Welcome to our four-part Strategy Smarts series designed to give you some practical trading templates which build on the concepts outlined in our Day Traders Toolbox and Power Patterns series. Today’s piece centres around Trend Days; what they are, how to spot them early and most importantly, how to trade them consistently.
10:18, 15 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com